All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Phase III CHRONOS-3 study evaluating copanlisib and rituximab combination meets primary endpoint
On October 14, 2020, it was announced that the phase III CHRONOS-3 study (NCT02367040), evaluating copanlisib in combination with rituximab for relapsed indolent non-Hodgkin lymphoma (iNHL), met its primary endpoint of significantly prolonging progression-free survival (PFS).1
Copanlisib
Copanlisib is an intravenously-administered pan inhibitor of phosphoinositide 3-kinase. In 2017, copanlisib received accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed follicular lymphoma, a decision based on the results of the phase II CHRONOS-1 trial (NCT01660451).
CHRONOS-32
The phase III CHRONOS-3 trial is a randomized, double-blind, placebo-controlled study investigating the safety and efficacy of copanlisib plus rituximab vs placebo plus rituximab in adult patients with relapsed iNHL. The study sought to determine whether copanlisib plus rituximab is superior to placebo plus rituximab in prolonging PFS in this setting.
Patients with follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, and lymphoplasmacytoid lymphoma/Waldenström’s macroglobulinemia who had received ≥ 1 line of prior therapy were enrolled. Additional inclusion criteria were a treatment-free interval of ≥ 12 months following last rituximab-based treatment or ineligibility for chemotherapy. Patients (N = 458) were randomized 2:1 to receive copanlisib plus rituximab vs placebo plus rituximab in the following dosing regimens:
- Copanlisib or placebo: Days 1, 8, and 15 of each 28-day cycle
- Rituximab:
- Weekly on Days 1, 8, 15, and 22 of Cycle 1
- Day 1 of Cycles 3, 5, 7, and 9
Full safety and efficacy data from the CHRONOS-3 study are due to be released later this year.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What is your preferred therapy class when planning treatment for a patient with R/R DLBCL after 2 or more lines of systemic therapy ?